All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 > 1% PD-L1 > 10% smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), pembrolizumab based treatment vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-045 (all population), 2017 0.73 [0.59; 0.91]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.57 [0.37; 0.88]
KEYNOTE-361 (P vs C), 2021 0.92 [0.77; 1.10]
KEYNOTE-361 (PC vs C), 2021 0.86 [0.72; 1.02]
0.81 [0.69 ; 0.94 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 46% 2,068 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-045 (all population), 2017 0.70 [0.57; 0.85]
0.70 [0.57 ; 0.85 ] KEYNOTE-045 (all population), 2017 1 0% 542 NA not evaluable PFS (extension)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.79; 1.16]
0.96 [0.79 ; 1.16 ] KEYNOTE-045 (all population), 2017 1 0% 542 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-045 (all population), 2017 0.98 [0.81; 1.19]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.89 [0.61; 1.29]
KEYNOTE-361 (P vs C), 2021 1.35 [1.12; 1.63]
KEYNOTE-361 (PC vs C), 2021 0.78 [0.65; 0.93]
0.99 [0.76 ; 1.28 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 83% 2,068 moderate not evaluable DORdetailed results KEYNOTE-045 (all population), 2017 4.66 [1.83; 11.87]
4.66 [1.83 ; 11.87 ] KEYNOTE-045 (all population), 2017 1 0% 88 NA not evaluable objective responses (ORR)detailed results KEYNOTE-045 (all population), 2017 2.08 [1.29; 3.34]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.86 [1.43; 10.46]
KEYNOTE-361 (P vs C), 2021 0.53 [0.39; 0.74]
KEYNOTE-361 (PC vs C), 2021 1.48 [1.10; 2.00]
1.47 [0.70 ; 3.10 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 92% 2,068 moderate not evaluable objective responses (ORR) (extension)detailed results KEYNOTE-045 (all population), 2017 2.16 [1.34; 3.48]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.56 [1.30; 9.71]
2.37 [1.54 ; 3.65 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 2 0% 706 moderate not evaluable AE (any grade)detailed results KEYNOTE-045 (all population), 2017 0.28 [0.10; 0.75]
0.28 [0.10 ; 0.75 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.61 [0.43; 0.86]
0.61 [0.43 ; 0.86 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable AE (grade 3-5)detailed results KEYNOTE-361 (P vs C), 2021 0.38 [0.26; 0.54]
KEYNOTE-361 (PC vs C), 2021 1.53 [1.01; 2.33]
0.76 [0.19 ; 3.00 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 96% 1,335 moderate not evaluable AE leading to death (grade 5)detailed results KEYNOTE-045 (all population), 2017 1.59 [0.65; 3.89]
KEYNOTE-361 (P vs C), 2021 3.49 [1.61; 7.56]
KEYNOTE-361 (PC vs C), 2021 3.74 [1.75; 7.95]
2.88 [1.73 ; 4.78 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 16% 1,856 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-045 (all population), 2017 0.63 [0.35; 1.11]
KEYNOTE-361 (P vs C), 2021 0.85 [0.56; 1.29]
KEYNOTE-361 (PC vs C), 2021 2.02 [1.42; 2.89]
1.05 [0.52 ; 2.14 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 87% 1,856 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.85 [0.44; 1.65]
0.85 [0.44 ; 1.65 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable STRAE (any grade)detailed results KEYNOTE-361 (P vs C), 2021 0.39 [0.26; 0.59]
KEYNOTE-361 (PC vs C), 2021 1.16 [0.83; 1.61]
0.68 [0.23 ; 1.96 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 94% 1,335 moderate not evaluable TRAE (any grade)detailed results KEYNOTE-045 (all population), 2017 0.17 [0.10; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.04; 0.14]
0.12 [0.05 ; 0.25 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 2 75% 1,165 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.19 [0.12; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.05; 0.12]
KEYNOTE-361 (PC vs C), 2021 1.19 [0.85; 1.67]
0.26 [0.05 ; 1.37 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 98% 1,856 moderate not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.14; 7.00]
1.00 [0.38 ; 2.69 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.25; 0.93]
0.48 [0.25 ; 0.93 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.68 [0.22 ; 13.01 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.07 [0.02; 0.31]
KEYNOTE-361 (P vs C), 2021 0.02 [0.01; 0.07]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.63; 1.20]
0.11 [0.01 ; 1.60 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 96% 1,856 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.13 [0.02; 1.09]
KEYNOTE-361 (P vs C), 2021 0.12 [0.02; 0.98]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.38; 2.50]
0.32 [0.07 ; 1.52 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 62% 1,856 moderate not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
KEYNOTE-361 (PC vs C), 2021 1.97 [0.18; 21.78]
3.59 [0.86 ; 14.94 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.06 [0.00; 1.02]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 0.24 [0.01; 5.43]
0.33 [0.05 ; 1.99 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 31% 1,856 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
KEYNOTE-361 (P vs C), 2021 0.38 [0.04; 3.63]
KEYNOTE-361 (PC vs C), 2021 0.32 [0.03; 3.14]
0.29 [0.07 ; 1.20 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.11 [0.19 ; 23.33 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.44 [0.24; 8.71]
KEYNOTE-361 (P vs C), 2021 0.90 [0.24; 3.40]
KEYNOTE-361 (PC vs C), 2021 1.38 [0.43; 4.39]
1.20 [0.55 ; 2.63 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.25 [0.07; 0.92]
KEYNOTE-361 (P vs C), 2021 0.50 [0.15; 1.63]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.33; 2.28]
0.53 [0.26 ; 1.06 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 12% 1,856 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.11 [0.19 ; 23.33 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.34 [0.16 ; 11.51 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
3.89 [0.41 ; 36.85 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
3.06 [0.31 ; 30.30 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 0.01 [0.00; 0.13]
KEYNOTE-361 (PC vs C), 2021 0.68 [0.38; 1.24]
0.09 [0.00 ; 7.03 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 89% 1,335 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.55 [0.12 ; 20.23 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
0.77 [0.09 ; 6.59 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
KEYNOTE-361 (P vs C), 2021 0.28 [0.06; 1.32]
KEYNOTE-361 (PC vs C), 2021 0.85 [0.31; 2.38]
0.54 [0.24 ; 1.19 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.65 [0.40 ; 17.69 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.19]
KEYNOTE-361 (P vs C), 2021 0.00 [0.00; 0.07]
KEYNOTE-361 (PC vs C), 2021 0.94 [0.67; 1.32]
0.04 [0.00 ; 2.29 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 91% 1,856 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 4.55 [0.20; 101.37]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
4.23 [0.47 ; 37.98 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 9.75 [0.53; 179.40]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
KEYNOTE-361 (PC vs C), 2021 2.96 [0.31; 28.57]
4.61 [1.15 ; 18.48 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
1.72 [0.24 ; 12.08 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 0.57 [0.02; 16.92]
KEYNOTE-361 (PC vs C), 2021 3.95 [0.44; 35.56]
2.23 [0.35 ; 14.10 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.05 [0.07 ; 16.88 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.32 [0.03; 3.07]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 3.99 [0.84; 18.92]
1.36 [0.32 ; 5.68 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 41% 1,856 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 0.02 [0.00; 0.13]
KEYNOTE-361 (PC vs C), 2021 0.80 [0.52; 1.24]
0.14 [0.00 ; 5.55 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 92% 1,335 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.36 [0.16 ; 11.68 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 0% 1,856 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 0.14 [0.02; 1.12]
KEYNOTE-361 (PC vs C), 2021 1.11 [0.42; 2.90]
0.49 [0.07 ; 3.55 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 68% 1,335 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.40 [0.10; 1.58]
0.40 [0.10 ; 1.58 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.27 [0.58; 8.88]
2.27 [0.58 ; 8.88 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.65 [0.37; 1.16]
0.65 [0.37 ; 1.16 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.14 [0.03; 0.63]
0.14 [0.03 ; 0.63 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.15; 0.40]
0.24 [0.15 ; 0.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cardiac disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.72 [0.16; 3.23]
0.72 [0.16 ; 3.23 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.35 [0.09; 1.34]
0.35 [0.09 ; 1.34 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.28 [0.89; 12.06]
3.28 [0.89 ; 12.06 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
0.96 [0.24 ; 3.87 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dry skin AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dysgeusia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.61 [0.38; 6.80]
1.61 [0.38 ; 6.80 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Endocrine disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Eye disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
3.86 [0.17 ; 85.92 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.63 [0.28; 1.42]
0.63 [0.28 ; 1.42 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.02 [0.00; 0.39]
0.02 [0.00 ; 0.39 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.42 [0.24; 0.75]
0.42 [0.24 ; 0.75 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.49 [0.28; 0.86]
0.49 [0.28 ; 0.86 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Headache AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 11.75 [0.65; 211.40]
11.75 [0.65 ; 211.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Infections and infestations AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.22 [0.72; 2.06]
1.22 [0.72 ; 2.06 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Injury, poisoning and procedure AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.45 [0.40; 5.19]
1.45 [0.40 ; 5.19 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Investigations AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.46 [0.26; 0.79]
0.46 [0.26 ; 0.79 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.07 [0.62; 1.84]
1.07 [0.62 ; 1.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
0.24 [0.03 ; 2.13 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Musculoskeletal and connective tissue disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.36 [0.59; 3.12]
1.36 [0.59 ; 3.12 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Myalgia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.72 [0.16; 3.23]
0.72 [0.16 ; 3.23 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Nervous system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.27 [0.10; 0.74]
0.27 [0.10 ; 0.74 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.18]
0.01 [0.00 ; 0.18 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.64 [0.11; 3.84]
0.64 [0.11 ; 3.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Renal and urinary disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.77 [1.31; 5.84]
2.77 [1.31 ; 5.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.63 [0.70; 3.80]
1.63 [0.70 ; 3.80 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.02; 1.31]
0.16 [0.02 ; 1.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.06; 15.41]
0.96 [0.06 ; 15.41 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Vascular disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.71 [0.85; 8.61]
2.71 [0.85 ; 8.61 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.06; 15.41]
0.96 [0.06 ; 15.41 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 08:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561